Cantor Fitzgerald analyst Eliana Merle maintained a Buy rating on AnaptysBio Inc (ANAB) today and set a price target of $140. The company’s shares opened today at $69.99.
According to TipRanks.com, Merle is a 1-star analyst with an average return of -6.1% and a 21.1% success rate. Merle covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, CymaBay Therapeutics, and Galapagos NV.
Currently, the analyst consensus on AnaptysBio Inc is a Strong Buy with an average price target of $131.50, representing an 87.9% upside. In a report issued on February 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $135 price target.
See today’s analyst top recommended stocks >>
Based on AnaptysBio Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5 million and GAAP net loss of $15.96 million. In comparison, last year the company earned revenue of $3 million and had a GAAP net loss of $6.86 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.
